Genetic mapping of a highly variable norovirus GII.4 blockade epitope: Potential role in escape from human herd immunity

Journal of Virology

Volumn 86, Issue 2, 2012, Pages 1214-1226

  Debbink, Kari ^a,b   Donaldson, Eric F ^a   Lindesmith, Lisa C ^a   Baric, Ralph S ^a,b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIGEN; EPITOPE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

AMINO ACID ANALYSIS; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGENIC VARIATION; ANTIVIRAL ACTIVITY; ARTICLE; CHIMERA; CONTROLLED STUDY; EPIDEMIC; GENE MAPPING; HERD IMMUNITY; LIGAND BINDING; NONHUMAN; NOROVIRUS; PRIORITY JOURNAL; PROTEIN INTERACTION; SEQUENCE HOMOLOGY; SEROLOGY; STRAIN DIFFERENCE; VIRUS IDENTIFICATION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; BLOOD GROUP ANTIGENS; CAPSID PROTEINS; EPITOPE MAPPING; GASTROENTERITIS; HUMANS; IMMUNITY, HERD; MICE; MOLECULAR SEQUENCE DATA; NOROVIRUS; SEQUENCE ALIGNMENT;

MIRIDAE; NOROVIRUS;

EID: 84856907832     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06189-11     Document Type: Article

References (50)

1. Allen DJ, Gray JJ, Gallimore CI, Xerry J, Iturriza-Gomara M. 2008. Analysis of amino acid variation in the P2 domain of the GII-4 norovirus VP1 protein reveals putative variant-specific epitopes. PLoS One 3:e1485.
2. Allen DJ, et al. 2009. Characterisation of a GII-4 norovirus variantspecific surface-exposed site involved in antibody binding. Virol. J. 6:150.
3. Atmar RL, Estes MK. 2006. The epidemiologic and clinical importance of norovirus infection. Gastroenterol. Clin. North Am. 35:275-290, viii.
4. Baric RS, et al. 2002. Expression and self-assembly of Norwalk virus capsid protein from Venezuelan equine encephalitis virus replicons. J. Virol. 76:3023-3030.
5. Bok K, et al. 2009. Evolutionary dynamics of GII. 4 noroviruses over a 34-year period. J. Virol. 83:11890-11901.
6. Bok K, et al. 2011. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc. Natl. Acad. Sci. U. S. A. 108: 325-330.
7. Bush RM, Fitch WM, Bender CA, Cox NJ. 1999. Positive selection on the H3 hemagglutinin gene of human influenza virus A. Mol. Biol. Evol. 16: 1457-1465.
8. Cannon JL, et al. 2009. Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J. Virol. 83:5363-5374.
9. Cao S, et al. 2007. Structural basis for the recognition of blood group trisaccharides by norovirus. J. Virol. 81:5949-5957.
10. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. 1982. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31:417-427.
11. Chen Y, et al. 2011. Crystallography of a lewis-binding norovirus, elucidation of strain-specificity to the polymorphic human histo-blood group antigens. PLoS Pathog. 7:e1002152.
12. Chenna R, et al. 2003. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 31:3497-3500.
13. Clarke IN, Lambden PR. 1997. The molecular biology of caliciviruses. J. Gen. Virol. 78(Pt. 2):291-301.
14. de Rougemont A, et al. 2011. Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens. J. Virol. 85:4057-4070.
15. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. 2008. Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol. Rev. 225:190-211.
16. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. 2010. Viral shapeshifting: norovirus evasion of the human immune system. Nat. Rev. Microbiol. 8:231-241.
17. El-Kamary SS, et al. 2010. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202:1649-1658.
18. Ferguson NM, Galvani AP, Bush RM. 2003. Ecological and immunological determinants of influenza evolution. Nature 422:428-433.
19. Glass RI, Parashar UD, Estes MK. 2009. Norovirus gastroenteritis. N. Engl. J. Med. 361:1776-1785.
20. Hager-Braun C, et al. 2010. Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis. J. Am. Soc. Mass Spectrom. 21:1687-1698.
21. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. 2002. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J. Virol. 76:12335-12343.
22. Jiang X, Wang M, Graham DY, Estes MK. 1992. Expression, selfassembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66:6527-6532.
23. Johnston CP, et al. 2007. Outbreak management and implications of a nosocomial norovirus outbreak. Clin. Infect. Dis. 45:534-540.
24. Koelle K, Cobey S, Grenfell B, Pascual M. 2006. Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science 314:1898-1903.
25. Koelle K, Ratmann O, Rasmussen DA, Pasour V, Mattingly J. 2011. A dimensionless number for understanding the evolutionary dynamics of antigenically variable RNA viruses. Proc. Biol. Sci. 278:3723-3730.
26. Lee BY, et al. 2011. Economic value of norovirus outbreak control measures in healthcare settings. Clin. Microbiol. Infect. 17:640-646.
27. Lee VJ, et al. 2010. Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains. Vaccine 28:6852-6857.
28. Lindesmith LC, Donaldson EF, Baric RS. 2011. Norovirus GII. 4 strain antigenic variation. J. Virol. 85:231-242.
29. Lindesmith LC, et al. 2008. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 5:e31.
30. LoBue AD, Lindesmith LC, Baric RS. 2010. Identification of crossreactive norovirus CD4+ T cell epitopes. J. Virol. 84:8530-8538.
31. Lochridge VP, Jutila KL, Graff JW, Hardy ME. 2005. Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions. J. Gen. Virol. 86:2799-2806.
32. Mattner F, et al. 2006. Risk groups for clinical complications of norovirus infections: an outbreak investigation. Clin. Microbiol. Infect. 12:69-74.
33. Mead PS, et al. 1999. Food-related illness and death in the United States. Emerg. Infect. Dis. 5:607-625.
34. Murata T, et al. 2007. Prolonged norovirus shedding in infants ≤6 months of age with gastroenteritis. Pediatr. Infect. Dis. J. 26:46-49.
35. Ogata T, et al. 2008. Human H5N2 avian influenza infection in Japan and the factors associated with high H5N2-neutralizing antibody titer. J. Epidemiol. 18:160-166.
36. Okada M, Tanaka T, Oseto M, Takeda N, Shinozaki K. 2006. Genetic analysis of noroviruses associated with fatalities in healthcare facilities. Arch. Virol. 151:1635-1641.
37. Patel MM, et al. 2008. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg. Infect. Dis. 14:1224-1231.
38. Prasad BV, et al. 1999. X-ray crystallographic structure of the Norwalk virus capsid. Science 286:287-290.
39. Reeck A, et al. 2010. Serological correlate of protection against norovirusinduced gastroenteritis. J. Infect. Dis. 202:1212-1218.
40. Ronquist F, Huelsenbeck JP. 2003. MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics 19:1572-1574.
41. Shanker S, et al. 2011. Structural analysis of histo-blood group antigen binding specificity in a norovirus GII.4 epidemic variant: implications for epochal evolution. J. Virol. 85:8635-8645.
42. Siebenga JJ, et al. 2010. Phylodynamic reconstruction reveals norovirus GII.4 epidemic expansions and their molecular determinants. PLoS Pathog. 6:e1000884.
43. Siebenga JJ, et al. 2007. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J. Virol. 81:9932-9941.
44. Souza M, Costantini V, Azevedo MS, Saif LJ. 2007. A human noroviruslike particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model. Vaccine 25:8448-8459.
45. Tan M, et al. 2008. Elucidation of strain-specific interaction of a GII-4 norovirus with HBGA receptors by site-directed mutagenesis study. Virology 379:324-334.
46. Vinje J, et al. 2000. Genetic polymorphism across regions of the three open reading frames of "Norwalk-like viruses." Arch. Virol. 145:223-241.
47. Vinje J, Koopmans MP. 2000. Simultaneous detection and genotyping of "Norwalk-like viruses" by oligonucleotide array in a reverse line blot hybridization format. J. Clin. Microbiol. 38:2595-2601.
48. Yang Y, et al. 2010. Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J. Virol. 84:9595-9607.
49. Yewdell JW. 2010. Monoclonal antibodies specific for discontinuous epitopes direct refolding of influenza A virus hemagglutinin. Mol. Immunol. 47:1132-1136.
50. Zolla-Pazner S. 2004. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 4:199-210.